[
  {
    "ts": null,
    "headline": "Bristol Myers, Bain Capital form new company to develop immunology drugs",
    "summary": "The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials.  Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success.  The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said.",
    "url": "https://finnhub.io/api/news?id=fe073da374a0f1e9ee956eb17c938800aa6b4e97c7ffd6a3c144051cffe70474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753739959,
      "headline": "Bristol Myers, Bain Capital form new company to develop immunology drugs",
      "id": 136113537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials.  Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success.  The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said.",
      "url": "https://finnhub.io/api/news?id=fe073da374a0f1e9ee956eb17c938800aa6b4e97c7ffd6a3c144051cffe70474"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb and Bain Capital Form New Immunology Company",
    "summary": "The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.",
    "url": "https://finnhub.io/api/news?id=bfb38ba48ed4072a8be30fa0f822e0559fa311a218fb2ebe7bee0756ceec3f87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753736700,
      "headline": "Bristol Myers Squibb and Bain Capital Form New Immunology Company",
      "id": 136113538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.",
      "url": "https://finnhub.io/api/news?id=bfb38ba48ed4072a8be30fa0f822e0559fa311a218fb2ebe7bee0756ceec3f87"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients",
    "summary": "PRINCETON, N.J. & BOSTON, July 28, 2025--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical...",
    "url": "https://finnhub.io/api/news?id=d2f4a14dbc2a8b81df53c866ba2c9d5de6d214e81702a3d583c1c6eed12f0b96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733760,
      "headline": "Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients",
      "id": 136113539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J. & BOSTON, July 28, 2025--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical...",
      "url": "https://finnhub.io/api/news?id=d2f4a14dbc2a8b81df53c866ba2c9d5de6d214e81702a3d583c1c6eed12f0b96"
    }
  },
  {
    "ts": null,
    "headline": "Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings",
    "summary": "Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.",
    "url": "https://finnhub.io/api/news?id=bb1b9e521f7f8d2bfbe7a4dfcc619b6b0845327db0080a1c03dfe0d06c503716",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753721970,
      "headline": "Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings",
      "id": 136108438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.",
      "url": "https://finnhub.io/api/news?id=bb1b9e521f7f8d2bfbe7a4dfcc619b6b0845327db0080a1c03dfe0d06c503716"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9b5515b331b1c190346fefd8dd497ca979b4d0477d2cc8f7ee249ac326304533",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720860,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "id": 136137050,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9b5515b331b1c190346fefd8dd497ca979b4d0477d2cc8f7ee249ac326304533"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
    "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
    "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753714860,
      "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
      "id": 136108007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
      "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712880,
      "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136108008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7"
    }
  },
  {
    "ts": null,
    "headline": "Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth",
    "summary": "Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=418175a819bc540f61217f89b83f420411a8296dab6c337005860b89940eaa66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711214,
      "headline": "Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth",
      "id": 136108443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=418175a819bc540f61217f89b83f420411a8296dab6c337005860b89940eaa66"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?",
    "summary": "BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=f70830f8cbd0141f6de70ea7c499261c59c4cf161be34563520c0b3eb9b4e37c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753709280,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?",
      "id": 136108346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=f70830f8cbd0141f6de70ea7c499261c59c4cf161be34563520c0b3eb9b4e37c"
    }
  },
  {
    "ts": null,
    "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "url": "https://finnhub.io/api/news?id=52d6407205e887b45efcbf9b2537bda50d4807e9cdd69e57c4fefcc5a985a03e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753708202,
      "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
      "id": 136108446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
      "url": "https://finnhub.io/api/news?id=52d6407205e887b45efcbf9b2537bda50d4807e9cdd69e57c4fefcc5a985a03e"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman Sachs analyst Asad Haider maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $56.00 price target, basing the rating on the company’s current market position. Haider stated that Bristol-Myers Squibb Company (NYSE:BMY) is […]",
    "url": "https://finnhub.io/api/news?id=7a68df133ebd7cc3796a80bfe8f4b2b59aa1ab4cfbab5ba55697bccdeed32c0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682898,
      "headline": "Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)",
      "id": 136108447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman Sachs analyst Asad Haider maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $56.00 price target, basing the rating on the company’s current market position. Haider stated that Bristol-Myers Squibb Company (NYSE:BMY) is […]",
      "url": "https://finnhub.io/api/news?id=7a68df133ebd7cc3796a80bfe8f4b2b59aa1ab4cfbab5ba55697bccdeed32c0f"
    }
  }
]